

THE WEINBERG GROUP INC.

June 2, 2000

Food and Drug Administration
Office of Device Evaluation
Document Mail Center (HFZ-401)
9200 Corporate Boulevard
Rockville, MD 20850

RE: PMA 990015/A010 INTERGEL® Adhesion Prevention Solution

To Whom It May Concern:

Enclosed are seven (7) copies of PMA 990015/A010 INTERGEL® Adhesion Prevention Solution. The document is comprised of one volume.

Please forward this submission to the following individuals:

Celia Witten, M.D., Ph.D. (1 copy)
Director, Division of General and Restorative Devices (HFZ-401)
Office of Device Evaluation
Center for Devices and Radiological Health
Food and Drug Administration
9200 Corporate Boulevard
Rockville, MD 20850

Stephen P. Rhodes, Ph.D. (6 copies)
Branch Chief, Plastic and Reconstructive Surgery Branch
Office of Device Evaluation
Center for Devices and Radiological Health
Food and Drug Administration
9200 Corporate Boulevard, Room 310N
Rockville, MD 20850

1220 Nineteenth St, NW, Suite 300

Washington, DC 20036-2400

Phone 202.833.8077

Fax 202.833.7057

e-mail science@weinberggroup.com

WASHINGTON

NEW YORK

SAN FRANCISCO

BRUSSELS

PARIS


Food and Drug Administration

June 2, 2000

Page 2

Thank you for your assistance. Should you have any questions, please contact me at 202-833-8077.

Very truly yours,



Karen M. Becker, Ph.D.

Worldwide Managing Director, Healthcare Products
THE WEINBERG GROUP INC.

KMB/kh

Enclosures

cc Georgiann Keyport, R.A.C.



LIFECORE

B I O M E D I C A L

June 1, 2000

Celia Witten, M.D., Ph.D.
Director, Division of General and Restorative Devices (HFZ-401)
Office of Device Evaluation, Center for Devices and Radiological Health
Food and Drug Administration
9200 Corporate Blvd.
Rockville, MD 20850

Re: INTERGEL® Adhesion Prevention Solution, PMA 990015/A010


Dear Dr. Witten:

Enclosed please find a major amendment to Lifecore Biomedical's INTERGEL® Solution PMA submitted by The Weinberg Group Inc. The purpose of this letter is to provide authorization from Lifecore Biomedical to The Weinberg Group to submit this information on our behalf.

Please don't hesitate to contact me should you have any questions or comments concerning this authorization.

Best regards,

LIFECORE BIOMEDICAL, INC.



Georgiann Keyport
Director of Regulatory and Clinical Affairs
Email: gmkeypo@lifecore.com

T: (612) 368-6294
F: (612) 368-4278

Enclosure

Lifecore Biomedical, Inc.

Major Amendment to INTERGEL® Adhesion Prevention Solution PMA P990015/A010

June 2, 2000

PMA AMENDMENT 010

**Lifecore Biomedical
INTERGEL® Adhesion Prevention Solution
PMA 990015/A010**

June 2, 2000

TABLE OF CONTENTS

SECTION I.	COVER LETTER
SECTION II.	PROPOSED INDICATIONS FOR USE (<i>REVISED</i>)
SECTION III.	AMENDMENT TO CLINICAL TRIAL REPORT: PROTOCOL PTL-0013/0022, MAY 31, 2000
SECTION IV.	SAFETY OF INTERGEL® SOLUTION FOR USE IN GYNECOLOGICAL PELVIC SURGERY

APPENDICES

Appendix A.	Clinical Validation of American Fertility Society Adnexal Adhesion Scoring System: Review of the Literature
Appendix B.	Effect of INTERGEL® Solution on Mortality and Abscess Formation After Intraperitoneal Infection in Rats. Study Report. May 31, 2000
Appendix C.	Summary of Safety and Effectiveness (<i>Revised</i>)
Appendix D.	Clinical Trial Report. Protocol PTL-0013/0022. Clinical Evaluation of Lubricoat 0.5% Ferric Hyaluronate Gel For the Reduction of Adhesions Following Peritoneal Cavity Surgery, A Multicenter Study of Safety and Efficacy, March 4, 1999